ArticleFrontiers in cell and developmental biology2024
Evaluation of prognostic risk factors of triple-negative breast cancer with
Article in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrating PET/CT-derived heterogeneity indices and composite risk scores improves prognostic stratification in breast cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- [18F]FDG PET/CT Radiomics in Untreated Breast Carcinoma: A Review of the Current State and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Establishment of a novel renal immune prognostic index to predict clinical outcomes in renal cell cancer patients who received surgery.Frontiers in oncology · 2025Article
- Impact of pre-therapeutic fasting plasma glucose on survival outcomes in advanced non-small cell lung cancer patients.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is a heterogeneous disease comprising various molecular subtypes, including Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER2) positive, and triple negative types, each with distinct biological characteristics and behaviors. Triple negative breast cancer (TNBC) remains a particularly challenging subtype worldwide. Our study aims to evaluate whether Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography ( Methods: We conducted a retrospective analysis of 95 TNBC patients who underwent preoperative Results: Among 95 TNBC patients, mean standardized uptake value (SUV Discussion: We found that SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.